<DOC>
	<DOCNO>NCT02582671</DOCNO>
	<brief_summary>This study seek determine effectiveness interferon-free ABBVIE REGIMEN ± RBV chronic hepatitis C virus infect participant across Ireland .</brief_summary>
	<brief_title>The Effectiveness ABT-450/r - Ombitasvir , + Dasabuvir , ± Ribavirin Patients With Chronic Hepatitis C -An Observational Study Ireland</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Treatmentnaïve experience participant confirm CHC , genotype 1 , receive combination therapy interferonfree ABBVIE REGIMEN ± RBV accord standard care line current local label If RBV coadministered ABBVIE REGIMEN , prescribe line current local label Participants must participate intend participate concurrent interventional therapeutic trial None</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Real World Effectiveness</keyword>
</DOC>